Skip to main content
Fig. 2 | Renal Replacement Therapy

Fig. 2

From: Linagliptin inhibits lipopolysaccharide-stimulated interleukin-6 production, intranuclear p65 expression, and p38 mitogen-activated protein kinase phosphorylation in human umbilical vein endothelial cells

Fig. 2

Effects of linagliptin on nuclear factor kappa-B (NFκB)/p65 translocation into lipopolysaccharide (LPS)-stimulated human umbilical vein endothelial cell (HUVEC) nuclei. HUVECs were treated with LPS and/or linagliptin. NFκB/p65 levels in the nuclear fraction were determined by ELISA after 5 h of treatment. *P < 0.05 vs. control; # P < 0.05 vs. LPS 1 μg/mL. Lina linagliptin

Back to article page

Renal Replacement Therapy

ISSN: 2059-1381

Contact us